The outcomes of several recent clinical trials, such as the EMPA-REG OUTCOME, CANVAS program, and DECLARE-TIMI 58 studies, have indicated the renal protective effects of SGLT2 inhibitors for T2DM patients [10–12]. Here, SLC5A2 is linked to type 2 diabetes mellitus.